Sniper
13-02-2004, Fri 6:07 PM
VITA upgraded at First Albany; target $8 (3.19 )
First Albany upgrades Orthovita to Buy from Neutral and raises their target to $8 from $3.65; while revs were disappointing, firm believes the co is well-positioned for strong rev growth through 2004-05, with several new product introductions on its current Vitoss scaffold bridging the gap until the launch of its next major biomaterial product, Cortoss, expected in 2008 at the earliest.
للمتابعه
الخبر جميل جدا ....
يا ريت المشاركه في تحليل الشركه
شاكر تعاونكم
First Albany upgrades Orthovita to Buy from Neutral and raises their target to $8 from $3.65; while revs were disappointing, firm believes the co is well-positioned for strong rev growth through 2004-05, with several new product introductions on its current Vitoss scaffold bridging the gap until the launch of its next major biomaterial product, Cortoss, expected in 2008 at the earliest.
للمتابعه
الخبر جميل جدا ....
يا ريت المشاركه في تحليل الشركه
شاكر تعاونكم